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Abstract 
Meningiomas are slow growing tumours of the meninges that affect brain and spinal 
cord. They account for a quarter of all primary brain tumours of the central nervous 
system. Accordingly to the WHO classification system, meningiomas are classified 
as grade I, atypical grade II and malignant grade III. Symptoms include headaches, 
focal neurological signs depending on localisation and seizures. The standard of 
treatment for these tumours is (radio)surgery. Nevertheless, it is estimated that one 
third of meningiomas cannot be operated or can be only partially resected, often 
leaving patients with significant morbidity. Current chemotherapies are not effective 
therefore it is a great medical need to find novel therapeutic options. We aimed to 
identify novel targets/biomarkers by analysing proteome and phosphoproteome of 
different grade meningiomas. Frozen tumour specimens as well as meningioma-
derived primary tumour cells were analysed by mass spectrometry to decipher 
proteome and phosphoproteome. -Phosphoproteins were isolated by an additional 
purification step. Overall we analysed 22 meningiomas (8 grade I, 8 grade II and 6 
grade III) for the proteome and 14 for the phosphoproteome (5 grade I, 5 grade II 
and 4 grade III). Comparative studies were performed to identify aberrantly 
overexpressed proteins and dysregulated pathways compared to healthy human 
meninges (N=3). Among the proteins found significantly upregulated in meningioma 
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vs. normal controls we identified STAT1, a member of the Jak/STAT signalling 
pathway. Validation studies performed on primary meningioma cells confirmed that 
the total amount of the protein was overexpressed about four times compared to 
normal human meningeal cells. Additionally, both phosphorylation sites (Y701 and 
S727) on STAT1 were aberrantly activated in meningioma cells but not in meningeal 
cells. Immunohistochemical analysis confirmed an upregulation of phosphorylated 
STAT1(Y701) especially on grade III meningiomas, in agreement with expression 
studies, although with high variability across samples. When the Jak/STAT signaling 
pathway gets activated in response to cytokines and growth factors, STAT1 is 
phosphorylated by activated JAKs and translocate into the nucleus to regulate gene 
expression. In primary meningioma cells we found that the amount of cytoplasmic 
pSTAT1(Y701) was markedly increased in vitro, without interferon stimulation and 
also in serum-free conditions, suggesting a cytokine-independent mechanism for 
pSTAT1 activation. Finally, STAT1 knocked down resulted in a significant reduction 
of cellular proliferation showed as a decrease in Ki67-positive cells and a decrease 
expression of Cyclin D1. These data altogether suggest STAT1 as a novel potential 
target in meningiomas. 
 
